US Food And drug management has recently been approved by Lenacapavir, more than 100 percent of the HIV vaccine and requires only two doses per year. Science He described the drug that is the most important drug of 2024.
In clinical trials, Lenacapavir proved working 99.9 percent in preventing HIV infection in sexual transmission to people weigh more than 35 pounds[35 kg]. Medicine, antiretroviral, does not work by renewing the immune system, but by preventing HIV from reproducing during the first time – directly, distracting the functioning of the CAPSID protein of its capsid virus. This happens as long as the body gets injections every six months.
Lenacapavir is already allowed in other countries as a treatment of HIV-positive people with resistant measures that prevent alternative treatments. However, before this week, the Prophylactic usage has not been allowed anywhere, making the FDA decision to be a great development in the fight against the HIV / AIDS epidemic.
The drug is not the first drug that can be taken inappropriately to protect about HIV infection: pre-exposure pills (pre) are already available in many countries, including the United States. But these should be taken daily, and ensure continuous access to these medicines, and that people really remember them to take them, it is a well known challenge. It is hoped that the lasting results of Lenacapavir will make it easier for people to protect the virus.
According to its Creator, Gilead Science, Lenacapavir will market under the commercial name of ZTUGO. The company has been dedicated to building 10 million doses in 2026.
“This is a history day for HIV to fight HIV. YEZTUGA is one of the most important scientific buildings for our time and gives a real opportunity to help the HIV epidemic,” said the statement on Wednesday.
However, Lenocapavir’s price can be a barrier to reach. YEZTUGO will have the annual monthly list of $ 28,218 per person in the US. Winnie Banyilima, the state-of-part area of the United Nations for the HIV / AIDS system (UNAIDS), a postponent that is not available for many Africans, where the drug has a great impact. About two thirds of HIV-positive people worldwide live in Africa under Sahara.
Gilead said in the timetable of the past year that he “formed a comprehensive, ongoing access strategy” in LectaVIvir, though the company has not yet provided details of how it will do this. One option can ‘be “a voluntary license,” when other companies are given permission to produce and sell regular types of patented products (usually) low countries. The University of Liverpool investigators in the UK are calculated that the importance of Lenacapavir year may be available a little as $ 25.
This story at the beginning appeared -Ome en español and translated from Spain.
